• PRM150 - TECHNOLOGY DIFFUSION IN HEALTHCARE- INSIGHTS FROM AN AGENT-BASED SIMULATION

    Oct 1, 2018, 00:00

  • PRS23 - PERSISTENCE TO COPD THERAPIES AND IMPACT ON COSTS RELATED TO HEALTHCARE CONSUMPTION- A FRENCH CLAIMS DATA STUDY

    Oct 1, 2018, 00:00

  • PRS54 - COST-EFFECTIVENESS ANALYSIS OF RESLIZUMAB FOR PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA INADEQUATELY CONTROLLED WITH HIGH-DOSE INHALED CORTICOSTEROIDS AND LONG-ACTING B2-AGONISTS IN SOUTH KOREA

    Oct 1, 2018, 00:00

  • PRS43 - COST-EFFECTIVENESS OF DOXYCYCLINE VERSUS PLACEBO IN OUTPATIENT-TREATED ACUTE EXACERBATIONS OF COPD- A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL

    Oct 1, 2018, 00:00

  • PMH60 - A COST-UTILITY ANALYSIS OF A MENTAL HEALTH PROMOTION PROGRAM IN SOCIAL ECONOMY COMPANIES IN FLANDERS

    Oct 1, 2018, 00:00

  • PMH59 - IDENTIFYING THE ASSOCIATION BETWEEN OUTCOMES AND QUALITY OF LIFE (QOL) OR HEALTH CARE RESOURCE UTILISATION (HCRU) IN SCHIZOPHRENIA- A SYSTEMATIC LITERATURE REVIEW (SLR)

    Oct 1, 2018, 00:00

  • PHP307 - REIMBURSEMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS IN EUROPE

    Oct 1, 2018, 00:00

  • PMD167 - HEALTH TECHNOLOGY ASSESSMENT OF MOBILE HEALTH APPLICATIONS- SLOW PROGRESS IN A FAST-PACED INDUSTRY?

    Oct 1, 2018, 00:00

  • PRM256 - ADJUSTMENT FOR THE IMPACT OF SUBSEQUENT THERAPIES NOT AVAILABLE IN UK ON OVERALL SURVIVAL (OS) IN CASTOR TRIAL- A SUBGROUP ANALYSIS IN SECOND-LINE (2L) PATIENTS

    Oct 1, 2018, 00:00

  • PRM120 - GRAPHICAL USER-FRIENDLY INTERFACE FOR COMPLEX HEALTH ECONOMIC MODELS BUILT IN R

    Oct 1, 2018, 00:00

  • PMS47 - COST-EFFECTIVENESS OF TOFACITINIB COMPARED WITH ADALIMUMAB IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN IRAN

    Oct 1, 2018, 00:00

  • PCV44 - EFFECTIVENESS OF SACUBITRIL/VALSARTAN VERSUS ENALAPRIL IN REDUCING MORTALITY AND HOSPITALIZATIONS COSTS FROM A MOROCCAN HOSPITAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • PSS60 - UTILITY ASSESSMENT FOR PEMPHIGUS HEALTH STATES USING VISUAL ANALOGUE SCALE AND TIME TRADE-OFF METHODS

    Oct 1, 2018, 00:00

  • PCN170 - COST-EFFECTIVENESS OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA- A CANADIAN SOCIETAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • PND134 - THE EFFECT OF PHYSICAL ACTIVITY ON THE MOTOR ASPECTS OF DAILY LIVING OF PARKINSON’S DISEASE PATIENTS

    Oct 1, 2018, 00:00

  • PMU122 - PATIENT-REPORTED OUTCOMES ON PERCEIVED WELL-BEING AMONG PATIENTS ON ANTI-INFLAMMATORY TREATMENT

    Oct 1, 2018, 00:00

  • PND129 - SATISFACTION AND EXPERIENCES OF PATIENTS TAKING FINGOLIMOD AND INVOLVED IN A PHARMACY-BASED PATIENT SUPPORT PROGRAM – SATFINO QUALITATIVE STUDY

    Oct 1, 2018, 00:00

  • PCP34 - BIOSIMILARS- WHAT’S THE ISSUE?

    Oct 1, 2018, 00:00

  • PMS65 - MYOTONIC DISORDERS- ANALYSIS FROM THE FRENCH DRG-BASED INFORMATION SYSTEM (PMSI)

    Oct 1, 2018, 00:00

  • PRM267 - WHAT IS DRIVING NICE-DECISION MAKING ON SINGLE-ARM TRIALS?

    Oct 1, 2018, 00:00

  • PMD23 - EASYPOD™ CONNECT OBSERVATIONAL STUDY (ECOS) – FRENCH CASE HISTORIES AND GROWTH OUTCOMES

    Oct 1, 2018, 00:00

  • PIN23 - CLINICAL AND ECONOMIC BURDEN OF INVASIVE MENINGOCOCCAL DISEASE IN FRANCE

    Oct 1, 2018, 00:00

  • PCN236 - IMPLICATIONS OF THE FAST EVOLVING THERAPEUTIC LANDSCAPE ON APPROPRIATE COMPARATORS IN ONCOLOGICAL AMNOG BENEFIT ASSESSMENTS

    Oct 1, 2018, 00:00

  • PCN39 - ESTIMATING THE MEAN PROGRESSION-FREE SURVIVAL OF NIRAPARIB, OLAPARIB AND RUCAPARIB COMPARED TO ROUTINE SURVEILLANCE FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT OVARIAN CANCER WITHOUT A BRCA MUTATION

    Oct 1, 2018, 00:00

  • PMD126 - DO OUTCOMES DIFFER BY THE TYPE OF ACUTE ISCHEMIC DIAGNOSIS? A RETROSPECTIVE ANALYSIS OF US HOSPITAL DATABASE

    Oct 1, 2018, 00:00

  • PHP295 - REVIEW OF POSSIBLE CAUSES OF VARIATION IN NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) TECHNOLOGY APPRAISALS

    Oct 1, 2018, 00:00

  • PCV96 - HEALTHCARE RESOURCE UTLISATION IN PATIENTS ON LIPID-LOWERING THERAPIES OUTSIDE OF WESTERN EUROPE- FINDINGS OF THE INTERNATIONAL CHOLESTEROL MANAGEMENT PRACTICE STUDY (ICLPS)

    Oct 1, 2018, 00:00

  • PCN299 - A REVIEW OF APPRAISAL TIMELINES IN ONCOLOGY- DOES REIMBURSEMENT THROUGH THE CANCER DRUGS FUND (CDF) DELAY PATIENT ACCESS?

    Oct 1, 2018, 00:00

  • PMU26 - BUDGET IMPACT ANALYSIS OF INTRAVENOUS BIOSIMILARS COMPARED WITH INTRAVENOUS ORIGINATORS AND SUBCUTANEOUS PRODUCTS

    Oct 1, 2018, 00:00

  • PRS57 - ECONOMIC EVALUATION OF SINGLE INHALER TRIPLE THERAPY FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) USING THE GALAXY MODEL

    Oct 1, 2018, 00:00

  • PGI4 - REAL-WORLD TRENDS IN CLINICAL CHARACTERISTICS OF INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS INITIATING VEDOLIZUMAB OVER TIME IN ISRAEL

    Oct 1, 2018, 00:00

  • PHP339 - MINIMALLY IMPORTANT DIFFERENCE (MID) OF EQ-5D-5L INDEX SCORE IN HONG KONG ADULTS POPULATION USING HONG KONG SCORING ALGORITHM

    Oct 1, 2018, 00:00

  • PCN131 - ASSESSING THE REAL-WORLD COST OF CARE IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER (MTNBC) IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PRM204 - PSYCHOMETRIC EVALUATION OF EORTC QLQ-C30 IN CUBAN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • PMS48 - COST PER RESPONDER ANALYSIS FOLLOWING A 24-WEEK PSORIATIC ARTHRITIS TREATMENT WITH SECUKINUMAB VERSUS ETANERCEPT FROM THE PORTUGUESE PAYER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCV24 - SAFETY AND EFFECTIVENESS OF CONTEMPORARY P2Y12 INHIBITORS IN EAST ASIAN PATIENTS WITH ACUTE CORONARY SYNDROMES- A NATIONWIDE POPULATION-BASED COHORT STUDY

    Oct 1, 2018, 00:00

  • PSY178 - FACTORS ASSOCIATED WITH OBESITY IN GREECE

    Oct 1, 2018, 00:00

  • PSY146 - SERIOUS ADVERSE REACTIONS REPORTED FOR DRUGS INVOLVED IN LAWSUITS FILED AGAINST THE BRAZILIAN PUBLIC HEALTH SYSTEM

    Oct 1, 2018, 00:00

  • PCP30 - COMPARISON REGARDING THE TRANSPARENCY OF REIMBURSEMENT DECISIONS FOR PHARMACEUTICALS USED TO TREAT DEPRESSION IN HUNGARY, ROMANIA, TURKEY AND CIS

    Oct 1, 2018, 00:00

  • PCV94 - NUTILIS CLEAR® IN DYSPHAGIC ADULT STROKE PATIENTS WITH ASPIRATION OF 10–14 POINTS ON GUSS SCALE

    Oct 1, 2018, 00:00

  • PCN370 - COMPARISONS ON THE CHANGE OF PSYCHOSOCIAL ILLNESS IMPACT ACROSS FOUR CANCER SURVIVORS

    Oct 1, 2018, 00:00

  • PCN291 - MARKET ACCESS FOR ONCO-HEMATOLOGY MEDICINES - VALUE OF SINGLE ARM STUDIES - ANALYSIS OF FRENCH HTA OPINIONS

    Oct 1, 2018, 00:00

  • PND148 - DEVELOPMENT OF A DIGITAL APP AND INNOVATIVE RECRUITMENT FOR AN INTERNATIONAL REAL-WORLD OBSERVATIONAL STUDY IN CHARCOT MARIE TOOTH DISEASE

    Oct 1, 2018, 00:00

  • PCV150 - HEALTH CARE RESOURCE USE AND QUALITY OF LIFE IN PATIENTS PRESCRIBED WITH SACUBITRIL/VALSARTAN IN PORTUGAL- A CROSS-SECTIONAL OBSERVATIONAL STUDY (PRIME STUDY)

    Oct 1, 2018, 00:00

  • PMU96 - DUTCH HEALTH STATE UTILITIES FOR INFERTILITY AND SUBFERTILITY

    Oct 1, 2018, 00:00

  • PCN369 - RELATION OF HEALTH RELATED QUALITY OF LIFE WITH INDICATORS OF NUTRITIONAL STATUS IN HEAD AND NECK CANCER PATIENTS ATTENDED IN A MEXICAN THIRD LEVEL PUBLIC FACILITY

    Oct 1, 2018, 00:00

  • PDB25 - PRESCRIBING PATTERN IN DIABETES MELLITUS PATIENTS IN SLOVENIA

    Oct 1, 2018, 00:00

  • PMS77 - DECLINE IN HEALTHCARE RESOURCE CONSUMPTION FOR PATIENTS WITH RHEUMATOID ARTHRITIS STARTING CERTOLIZUMAB PEGOL THERAPY IN FRANCE (THE ECLAIR STUDY)

    Oct 1, 2018, 00:00

  • PCV37 - IDENTIFICATION OF FACTORS AFFECTING READMISSIONS IN HEART FAILURE PATIENTS

    Oct 1, 2018, 00:00

  • PCN121 - BSC COST IN TERMINAL CANCER PATIENTS IN KOREA

    Oct 1, 2018, 00:00

  • PHP21 - METHODOLOGY OF IDENTIFICATION OF RISK GROUPS UNDER PHARMACEUTICAL GUIDELINES IN A SPECIAL REGIME INSURER IN COLOMBIA

    Oct 1, 2018, 00:00

  • PCN88 - NET IMPACT ANALYSIS OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN THE TREATMENT OF ADULTS WITH MULTIPLE MYELOMA FOR QUEBEC

    Oct 1, 2018, 00:00

  • PHP314 - THE RISE OF NICE ADVICE ON THE USE OF PHARMACEUTICALS, MEDICAL DEVICES AND DIGITAL HEALTH CARE IN THE NHS

    Oct 1, 2018, 00:00

  • PSY60 - ORPHAN VERSUS ULTRA-ORPHAN DRUGS PRICES IN ENGLAND

    Oct 1, 2018, 00:00

  • PRM42 - COST MODEL OF SWITCHING FROM ENBREL TO ETANERCEPT BIOSIMILARS, FOR NON MEDICAL REASONS, IN RHEUMATOID ARTHRITIS PATIENTS IN SPAIN

    Oct 1, 2018, 00:00

  • PHP333 - ADDRESSING THE CHALLENGE OF CHRONICITY IN A REGION OF SPAIN. TAKING STEPS TOWARDS A PARTNERSHIP BETWEEN THE HEALTH CARE ADMINISTRATION AND THE PHARMACEUTICAL INDUSTRY

    Oct 1, 2018, 00:00

  • Development of a Patient-Reported Outcome Measure for Geriatric Care- The Older Persons and Informal Caregivers Survey Short Form

    Oct 1, 2018, 00:00

  • PCV135 - NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS PRESCRIPTION MONITORING- HOW TO OPTIMIZE VIGILANCE IN STROKE PREVENTION

    Oct 1, 2018, 00:00

  • PHP344 - AN ECONOMIC EVALUATION OF GENERIC DRUG ENTRIES IN TURKISH PHARMACEUTICAL MARKET

    Oct 1, 2018, 00:00

  • QL3 - EQ-5D-5L IS MORE RESPONSIVE THAN EQ-5D-3L TO TREATMENT BENEFIT OF CATARACT SURGERY

    Oct 1, 2018, 00:00

  • PHP97 - NONADHERENCE TO TACROLIMUS IN ADULT LIVER AND KIDNEY TRANSPLANTATION IS ASSOCIATED WITH A HIGHER RISK OF EFFICACY FAILURE- REAL-WORLD EVIDENCE FROM ITALIAN ADMINISTRATIVE DATABASES

    Oct 1, 2018, 00:00

  • PCN106 - ECONOMIC BURDEN OF END-OF-LIFE AGGRESSION IN LUNG CANCER PATIENTS FROM THE FRENCH HEALTH INSURER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PUK39 - A CRITICAL APPRAISAL OF THE PRINCIPAL GUIDELINES FOR NEUROGENIC LOWER URINARY TRACT DYSFUNCTION USING THE AGREE II INSTRUMENT

    Oct 1, 2018, 00:00

  • PMS87 - IMPACT OF SERIOUS ILLNESS MEDICAL ASSISTANCE POLICY ON PERSISTENCE WITH TERIPARATIDE IN OSTEOPOROSIS PATIENTS IN QINGDAO, CHINA

    Oct 1, 2018, 00:00

  • PHP132 - CAN BLOCKCHAIN TECHNOLOGY IMPROVE THE QUALITY OF CLINICAL TRIAL EVIDENCE? – A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP311 - UPTAKE OF JOINTLY PRODUCED EUNETHTA HEALTH TECHNOLOGY ASSESSMENTS- WHERE ARE WE NOW?

    Oct 1, 2018, 00:00

  • PMS71 - SECULAR TRENDS IN THE INITIATION OF THERAPY IN SECONDARY FRACTURE PREVENTION IN EUROPE- A MULTI-NATIONAL STUDY INCLUDING DATA FROM DENMARK, SPAIN, AND THE UK.

    Oct 1, 2018, 00:00

  • PCV69 - COST-EFFECTIVENESS OF IVABRADINE AS A PHARMACOTHERAPY OPTION FOR PATIENTS WITH CONGESTIVE HEART FAILURE- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PCN255 - CERVICAL AND BREAST CANCER IN KAZAKHSTAN BEFORE AND AFTER THE INTRODUCTION OF SCREENING- AN INTERRUPTED TIME SERIES ANALYSIS

    Oct 1, 2018, 00:00

  • PHP361 - PIM AND EAMS- THE IMPACT OF PROMISING MEDICINE DESIGNATION IN ACHIEVING PATIENT ACCESS

    Oct 1, 2018, 00:00

  • PMD118 - SEROLOGY TESTING IN SCHOOL-AGED CHILDREN WITH ASTHMA, IN THE UK, COULD LEAD TO SUBSTANTIAL COST SAVINGS FOR THE NHS- A POPULATION-BASED SIMULATION STUDY

    Oct 1, 2018, 00:00

  • HT4 - PAN-EUROPEAN HTA – WHERE WE HAVE BEEN, WHERE WE ARE GOING?

    Oct 1, 2018, 00:00

  • PMU5 - THE ROLE OF MULTIMORBIDITY ON EARLY RETIREMENT IN EUROPE - RESULTS FROM THE SURVEY OF HEALTH, AGEING AND RETIREMENT IN EUROPE (SHARE)

    Oct 1, 2018, 00:00

  • PDB85 - A 10 YEAR COST-EFFECTIVENESS ANALYSIS (CEA) OF THE DIABETES PREVENTION PROGRAM OUTCOMES STUDY (DPP/DPPOS)- CLARIFYING THE PREVIOUS CONFUSION

    Oct 1, 2018, 00:00

  • PRM128 - VALIDATION AND CONCEPTUAL DESIGN OF A HEALTH ECONOMIC MODEL FOR ANAEMIA TREATMENT IN MYELODYSPLASTIC SYNDROME

    Oct 1, 2018, 00:00

  • PND7 - AN EXPLORATORY ANALYSIS OF EFFICACY OF OCRELIZUMAB FOR MULTIPLE SCLEROSIS PATIENTS WITH INCREASED DISABILITY

    Oct 1, 2018, 00:00

  • PHP345 - INNOVATIVE PAYMENT MODELS FOR BREAKTHROUGH THERAPIES

    Oct 1, 2018, 00:00

  • PHP141 - THE PRIVATE HEALTHCARE MARKET IN BRAZIL- A REVIEW OF 18 YEARS OF PROGRESS

    Oct 1, 2018, 00:00

  • PCN82 - BUDGET IMPACT ANALYSIS OF ALECTINIB FOR THE TREATMENT OF PATIENTS WITH UNTREATED ALK-REARRANGED NSCLC IN ITALY

    Oct 1, 2018, 00:00

  • PCP33 - COULD THE US ADMINISTRATION IMPOSE DRUG PRICE RAISES IN THE EUROPEAN UNION (EU)?

    Oct 1, 2018, 00:00

  • PRM209 - HOW DO WE MEASURE UTILITIES OUTSIDE OF TRIALS IN RARE DISEASES?

    Oct 1, 2018, 00:00

  • PMD54 - DRUG-COATED BALLOON THERAPY FOR TREATMENT OF CRITICAL LIMB ISCHEMIA IN FEMOROPOPLITEAL ARTERY DISEASE- ECONOMIC ANALYSIS FOR THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PHP119 - DISRUPTION IN PATIENT ACCESS TO INNOVATIVE THERAPY IN FRANCE AFTER INTERRUPTION OF NOMINATIVE TEMPORARY AUTHORISATION FOR USE

    Oct 1, 2018, 00:00

  • PSY188 - USE OF MANAGED ENTRY AGREEMENTS IN INFLAMMATORY DISORDERS AMONG KEY HEALTH TECHNOLOGY ASSESSMENT AGENCIES

    Oct 1, 2018, 00:00

  • PCN110 - COSTS ASSOCIATED WITH TRACHEA, BRONCHUS AND LUNG CANCER IN RUSSIA IN 2016 YEAR

    Oct 1, 2018, 00:00

  • PRS38 - COST-CONSEQUENCE ANALYSIS OF FLUTICASONE FUROATE/VILANTEROL FOR ASTHMA MANAGEMENT IN SPAIN- AN ANALYSIS BASED ON THE SALFORD LUNG STUDY IN ASTHMA

    Oct 1, 2018, 00:00

  • PCV34 - A REVIEW ASSESSING THE INCIDENCE AND PREVALENCE OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION

    Oct 1, 2018, 00:00

  • PMD48 - COSTS IN THE DIAGNOSIS OF SPANISH PATIENTS WITH SUSPECTED RHEUMATOID ARTHRITIS DEPENDS ON THE CCP ASSAY USED – A COMPARISON OF AUTOMATED CCP 2 AND CCP 3 ASSAYS

    Oct 1, 2018, 00:00

  • PDB66 - INSULIN GAP IN TYPE 2 DIABETES- IS IT COST EFFECTIVE TO INTENSIFY TREATMENT? EVIDENCE FROM PORTUGAL USING REAL WORLD DATA

    Oct 1, 2018, 00:00

  • PMS19 - A BUDGET IMPACT ANALYSIS OF INTRODUCING A FORCED TREATMENT PATHWAY USING THE LOWEST PRICED ANTI-TUMOR NECROSIS FACTOR AGENT FOR RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS IN THE PHILIPPINES

    Oct 1, 2018, 00:00

  • PMD104 - COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF TREATING DIABETIC FOOT ULCERS WITH URGOSTART COMPARED TO A NEUTRAL DRESSING.

    Oct 1, 2018, 00:00

  • PMD24 - ASSOCIATION BETWEEN IOL DESIGN AND INCIDENCE OF PCO AND ND-YAG CAPSULOTOMY- A RETROSPECTIVE REAL WORLD EVIDENCE STUDY IN THE UK

    Oct 1, 2018, 00:00

  • PDB76 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO LIRAGLUTIDE BASED ON CARDIOVASCULAR OUTCOME TRIALS

    Oct 1, 2018, 00:00

  • PHP276 - A REVIEW OF THE IMPACT OF INTEGRATED SCIENTIFIC ADVICE FOR THE OPTIMISATION OF EVIDENCE GENERATION FOR HTA APPRAISALS

    Oct 1, 2018, 00:00

  • PSY20 - REAL WORLD TREATMENT PERSISTANCE OF GOLIMUMAB IN THE MANAGEMENT OF IMMUNE-MEDIATED RHEUMATIC DISEASES (IMRDS) IN EUROPE- A SYSTEMATIC LITERATURE REVIEW (SLR)

    Oct 1, 2018, 00:00

  • PDB128 - COMPARISON OF PATIENT ACTIVATION LEVELS ACROSS VARIOUS CONDITIONS IN THE US AND EU5

    Oct 1, 2018, 00:00

  • PCN156 - PHARMACOECONOMICS OF NIMOTUZUMAB IN PATIENTS WITH HEAD AND NECK CANCER IN CUBA

    Oct 1, 2018, 00:00

  • PIN16 - BUDGET IMPACT ANALYSIS OF INTRODUCING A READY-TO-USE, FULLY-LIQUID, PAEDIATRIC, HEXAVALENT VACCINE FOR CHILDHOOD IMMUNISATION IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PRM140 - UTILIZING ADVANCED DATA ANALYSIS AND VISUALIZATION, POWERED BY ARTIFICIAL INTELLIGENCE, TO ANALYZE PRICE MIGRATION DATA FOR ONCOLOGY PRODUCTS

    Oct 1, 2018, 00:00

  • PRM132 - MODELING MULTIPLE CARDIOVASCULAR EVENT HISTORY USING NESTED PARTITIONED SURVIVAL MODELS

    Oct 1, 2018, 00:00

  • PSY216 - THE RELATIONSHIP BETWEEN HEALTH-RELATED QUALITY OF LIFE AND CLINICAL VERSUS SELF-REPORTED BODY MASS INDEX

    Oct 1, 2018, 00:00

  • PMU43 - THE COST OF INFORMAL CARE IN HUNGARY- A POOLED ANALYSIS OF 14 CROSS-SECTIONAL STUDIES

    Oct 1, 2018, 00:00

  • PSY39 - QUANTIFYING WORLDWIDE EVIDENCE TO ESTIMATE THE RISK OF TRANSMITTING CREUTZFELDT-JAKOB DISEASE VIA SURGICAL PROCEDURES

    Oct 1, 2018, 00:00

  • PIH53 - COMPARISON OF THE EQ-5D-5L AND THE EQ-5D-3L USING INDIVIDUAL PATIENT DATA FROM REFORM TRIAL

    Oct 1, 2018, 00:00

  • PRM66 - AN EXPLORATION OF THE METHODOLOGY FOR CONSIDERING TREATMENT DURATION IN BUDGET IMPACT ANALYSES IN ONCOLOGY- A CASE STUDY IN SECOND LINE ADVANCED RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PND53 - MODEL-BASED ECONOMIC EVALUATIONS OF TREATMENTS FOR PARKINSON’S DISEASE- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMD63 - POTENTIAL LONG-TERM SAVINGS RESULTED FROM THE INTRODUCTION OF INVASIVE EEG MONITORING AS A PREOPERATIVE DIAGNOSTIC PROCEDURE IN EPILEPSY SURGERY IN HUNGARY

    Oct 1, 2018, 00:00

  • PND99 - CYSTIC FIBROSIS THERAPIES - KEY DRIVERS BEHIND DIFFERING HTA DECISIONS

    Oct 1, 2018, 00:00

  • PSS55 - COMPARATIVE EFFECTIVENESS OF INTEGRATED LOCAL TREATMENTS OF GENERALIZED PERIODONTITIS AND CHRONIC GINGIVITIS

    Oct 1, 2018, 00:00

  • PHP227 - THE CURRENT REIMBURSEMENT LANDSCAPE FOR DIGITAL HEALTH IN THE UK- HOW FAR ARE WE FROM A CENTRALISED, NATIONAL SYSTEM?

    Oct 1, 2018, 00:00

  • PDB20 - PERSISTENCE TO LIRAGLUTIDE THERAPY IS ASSOCIATED WITH BETTER GLYCEMIC AND WEIGHT CONTROL IN PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PHP225 - ASSESSMENT OF THE UNIT COSTS IN IMAGING ACTS- THE EXAMPLE OF MRI AND CT-SCAN ACTS IN FRANCE

    Oct 1, 2018, 00:00

  • PDB45 - COSTS OF PREVENTION, MONITORING AND TREATMENT OF IODINE DEFICIENCY DISORDERS IN GERMANY

    Oct 1, 2018, 00:00

  • PHP140 - CURRENT CHALLENGES AND POTENTIAL SOLUTION FOR PRICING REGULATORY AND REIMBURSEMENT FRAMEWORK OF INNOVATIVE DRUGS IN EGYPT

    Oct 1, 2018, 00:00

  • PCN92 - THE EVALUATION OF THE ECONOMIC EFFICIENCY OF LENVATINIB IN COMBINATION WITH EVEROLIMUS IN RUSSIAN PATIENTS WITH DISSEMINATED RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PMD124 - CLINICAL, PATIENT-REPORTED OUTCOME MEASURES (PROMS) AND ECONOMIC OUTCOMES ASSOCIATED WITH ENHANCED RECOVERY PROGRAMS IN BARIATRIC SURGERY IN EUROPE, THE MIDDLE EAST AND AFRICA- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCV5 - REAL-WORLD LDL-C CHANGES EXPERIENCED WITH LOMITAPIDE MODELLED TO POTENTIALLY INCREASE LIFE-EXPECTANCY IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)

    Oct 1, 2018, 00:00

  • PCV33 - THE RATE OF CARDIOVASCULAR EVENTS IN DIABETIC PATIENTS IN COLOMBIA

    Oct 1, 2018, 00:00

  • PHP292 - ROADMAP FOR IMPLEMENTATION OF HEALTH TECHNOLOGY ASSESSMENT IN ROMANIA

    Oct 1, 2018, 00:00

  • PHP354 - THE IMPACT OF DATA PRIVACY REGULATIONS ON DRUG UTILIZATION DATA SHARING FOR INNOVATIVE PRICING ARRANGEMENTS

    Oct 1, 2018, 00:00

  • PHP200 - A REVIEW OF ACHIEVEMENTS AND CHALLENGES OF IRAN’S HEALTH TRANSFORMATION PLAN

    Oct 1, 2018, 00:00

  • PIN112 - HEALTH TECHNOLOGY ASSESSMENT OF THE AVAILABLE NRTI BACKBONES IN ITALY

    Oct 1, 2018, 00:00

  • PCN128 - COSTS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AND FOLLICULAR LYMPHOMA (FL) – A RETROSPECTIVE ANALYSIS OF JAPANESE CLAIMS DATA

    Oct 1, 2018, 00:00

  • PDB3 - THE IMPACT OF GLYCATED HEMOGLOBIN CONTROL ON MORBIDITY AND SURVIVAL AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PHP106 - IMPACT OF ACCESS RESTRICTION ON USE OF SHORT-ACTING PRESCRIPTION OPIOIDS IN A US HEALTH PLAN

    Oct 1, 2018, 00:00

  • PSY151 - REAL-WORLD IMPACT OF HIGH CONCENTRATION NON-AVIAN HIGH MOLECULAR WEIGHT HYALURONAN ON UTILIZATION PATTERNS OF PAIN MEDICATIONS AMONG PATIENTS WITH OSTEOARTHRITIS OF KNEE

    Oct 1, 2018, 00:00

  • PSY142 - THE ACCESS (TIMING AND AVAILABILITY) OF ORPHAN MEDICINE USE AND ITS DETERMINANTS AMONG OECD COUNTRIES FROM 2006 THROUGH 2016

    Oct 1, 2018, 00:00

  • PMD46 - COST-COST MODEL FOR RULING OUT CORONARY ARTERY DISEASE IN SYMPTOMATIC PATIENTS WITH ULTRA-SENSITIVE PHONOCARDIOGRAPHY IN THE GERMAN AMBULATORY SECTOR

    Oct 1, 2018, 00:00

  • PCN93 - ECONOMIC MODELING FOR THE US OF INTRAVENOUS VS SUBCUTANEOUS RITUXIMAB IN NON-HODGKIN’S LYMPHOMA TREATED WITH R-CHOP

    Oct 1, 2018, 00:00

  • PND93 - THE IMPACT OF MYASTHENIA GRAVIS (MG) ON HEALTHCARE RESOURCE UTILIZATION- EMPIRICAL EVIDENCE FROM A US REGISTRY SAMPLE

    Oct 1, 2018, 00:00

  • PSY185 - ALTERNATIVE METHODOLOGIES IMPLEMENTED BY HTA AGENCIES FOR ORPHAN DRUGS- A SCOPING REVIEW

    Oct 1, 2018, 00:00

  • PCN240 - ALL-COMERS VS. BIOMARKER BASED PATIENT SELECTION FOR BIOTHERAPIES IN ONCOLOGY- IMPACT ON DRUG DEVELOPMENT AND MARKET ACCESS

    Oct 1, 2018, 00:00

  • PDB27 - CLINICAL INERTIA IN RELATION TO BARRIERS TO PROGRESSION TO INJECTABLE THERAPY IN TYPE 2 DIABETES- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN211 - PATIENT CASE-MIX OF A TERTIARY CLINICAL CENTRE WITH PATIENTS DIAGNOSED WITH MALIGNANT MELANOMA BETWEEN 2012-2015

    Oct 1, 2018, 00:00

  • PIH24 - MODELLED EFFECTS OF A PEDIATRIC TRIPLE-CHAMBER-BAG (3CB) SYSTEM ON PAYER COSTS AND CLINICAL OUTCOMES IN PRE-TERM NEONATES ACROSS FRANCE, GERMANY AND ITALY

    Oct 1, 2018, 00:00

  • PMU34 - PRICE ANALYSIS OF VACCIENS MARKETED IN THE GULF COOPERATION COUNCIL COUNTRIES- A CROSS-SECTIONAL STUDY

    Oct 1, 2018, 00:00

  • PMD179 - PATIENTS’ USABILITY OF SIX MOST USED DRY-POWDER INHALERS IN ASTHMA AND COPD

    Oct 1, 2018, 00:00

  • PHP213 - A RETROSPECTIVE REVIEW OF REIMBURSEMENT DECISIONS BY THE HAUTE AUTORITÉ DE SANTÉ IN 2017 - UNDERLYING RATIONALE FOR MEDICINAL PRODUCTS WITH INSUFFICIENT ACTUAL MEDICAL BENEFIT

    Oct 1, 2018, 00:00

  • PRM219 - A NOVEL MEASURE OF DRUG BENEFIT-RISK ASSESSMENT BASED ON SCALE LOSS SCORE (SLOS)

    Oct 1, 2018, 00:00

  • PHP212 - A DECADE OF PUBLIC-PRIVATE PARTNERSHIPS (PDPS) IN BRAZIL- AN EXPLORATORY ANALYSIS OF PROGRESS AND CHALLENGES

    Oct 1, 2018, 00:00

  • PHP183 - PRICE DIFFERENCE OF MEDICINES DISPENSED IN COMMUNITY PHARMACIES AND IN THE HOSPITAL SECTOR - AN ANALYSIS ON THE MEDICINES FINANCED ON THE BASIS OF HOSPITAL SERVICE TARIFFS

    Oct 1, 2018, 00:00

  • PRM92 - INITIAL DEVELOPMENT OF INTELLIGENCE ON HEALTH CARE DATA IN BRASIL- FACING THE OBSTACLES

    Oct 1, 2018, 00:00

  • QL4 - ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH METASTATIC MELANOMA IN REAL CLINICAL PRACTICE IN FRANCE

    Oct 1, 2018, 00:00

  • PDB70 - ECONOMIC EVALUATION OF THE USE OF RECOMBINANT HUMAN EPIDERMAL GROWTH FACTOR (HEBERPROT-P®) AS AN ADJUVANT OF CONVENTIONAL THERAPY FOR THE TREATMENT OF DIABETIC FOOT ULCER

    Oct 1, 2018, 00:00

  • PMD173 - TREATMENT DIFFERENCES IN CHILDREN BURN CARE IN GERMANY BETWEEN BURN CENTERS AND NON-CENTERS

    Oct 1, 2018, 00:00

  • PND19 - INCIDENCE OF EPILEPSY AFTER STROKES AND REAL-WORLD ANTIEPILEPTIC DRUG TREATMENT

    Oct 1, 2018, 00:00

  • PMS8 - REAL-WORLD USE OF PROPHYLACTIC ANTIBIOTICS IN TOTAL KNEE ARTHROPLASTY

    Oct 1, 2018, 00:00

  • PSY130 - THE RELATIONSHIP BETWEEN DISEASE TYPE AND CONDITIONAL OR EXCEPTIONAL APPROVAL BY EMA FOR ORPHAN DRUGS IN 2017

    Oct 1, 2018, 00:00

  • PCN344 - NUTRITION BEHAVIOUR OF PATIENTS WITH BREAST CANCER

    Oct 1, 2018, 00:00

  • PCN102 - EXTRA-COST OF BRAIN METASTASES IN PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) - A FRENCH NATIONAL HOSPITAL DATABASE ANALYSIS

    Oct 1, 2018, 00:00

  • PCV115 - QUALITY OF INR CONTROL AND SWITCHING TO DOAC BETWEEN WOMEN AND MEN WITH ATRIAL FIBRILLATION TREATED WITH VITAMIN K ANTAGONISTS IN SPAIN. A POPULATION-BASED, REAL-WORLD STUDY.

    Oct 1, 2018, 00:00

  • PRS73 - THE BUDGET IMPACT OF NICOTINIC SUBSTITUTE REIMBURSEMENT

    Oct 1, 2018, 00:00

  • PCV4 - NON CARDIOVASCULAR COMORBITY AND PROGNOSIS OF CONGESTIVE HEART FAILURE

    Oct 1, 2018, 00:00

  • PMS11 - ESTIMATING THE PREVALENCE, AND DESCRIBING THE MEDICAL HISTORY AND TREATMENT PATTERNS OF PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN GERMANY – AN APPROACH USING A CLAIMS DATABASE

    Oct 1, 2018, 00:00

  • PRM184 - ANALYSIS OF UTILITY VALUES USED IN NICE APPRAISALS OF HIGHLY SPECIALISED TECHNOLOGIES

    Oct 1, 2018, 00:00

  • PCN307 - APPLYING MULTI-CRITERIA DECISION ANALYSIS (MCDA) AS AN EVIDENCE BASED HEALTH TECHNOLOGY ASSESSMENT IN HEALTH CARE DECISION MAKING IN EGYPT

    Oct 1, 2018, 00:00

  • PGI7 - ROBUST ESTIMATES CONCERNING THE HCV ELIMINATION STRATEGY IN GREECE. COMBINING THE RESULTS FROM TWO DIFFERENT MATHEMATICAL MODELS

    Oct 1, 2018, 00:00

  • PRM76 - WHAT PHYSICIANS WANT- SEARCH AND EVIDENCE SOURCE TRENDS IN THE TRIP HEALTHCARE DATABASE

    Oct 1, 2018, 00:00

  • PSY157 - EMERGING RHEUMATOID ARTHRITIS AND PSORIASIS BIOLOGICS- HOW TO THRIVE IN THE FACE OF BIOSIMILAR COMPETITION?

    Oct 1, 2018, 00:00

  • PCN235 - COMBINATION ONCOLOGY THERAPIES IN THE EU5- NAVIGATING THE ROAD TO REIMBURSEMENT AND OPTIMIZING UPTAKE IN MALIGNANT MELANOMA

    Oct 1, 2018, 00:00

  • PCN123 - EVALUATION OF DRUG THERAPY COSTS FOR PATIENTS WITH BREAST CANCER, MELANOMA AND RENAL CELL CARCINOMA IN MOSCOW IN 2016-2017

    Oct 1, 2018, 00:00

  • PGI41 - CLINICAL CHARACTERISTICS OF BIOLOGIC TREATED CROHN’S DISEASE PATIENTS WITH AND WITHOUT PRIOR SURGERY IN EUROPEAN UNION

    Oct 1, 2018, 00:00

  • PMD11 - STAGING INVESTIGATION STRATEGIES FOR DISTANT METASTASES DETECTION IN WOMEN WITH BREAST CANCER- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Oct 1, 2018, 00:00

  • PCV79 - REAL-WORLD COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH VITAMIN K ANTAGONISTS IN THE CONTEXT OF STROKE PREVENTION IN ATRIAL FIBRILLATION IN FRANCE

    Oct 1, 2018, 00:00

  • PCN99 - EVALUATING THE INCREASING STRAIN OF IMMUNOTHERAPIES (PD-1/PD-L1) ON PUBLIC HEALTHCARE SYSTEMS IN T5 + US

    Oct 1, 2018, 00:00

  • PHP84 - INVESTIGATING USAGE OF REFERENCE COUNTRIES FOR PRICING AND HEALTH TECHNOLOGY ASSESSMENT OF MEDICINES IN CEE COUNTRIES

    Oct 1, 2018, 00:00

  • PMD130 - HEALTH TECHNOLOGY ASSESSMENT (HTA) OF MEDICAL DEVICES IN EUROPE- THE CALM BEFORE THE STORM OR ALREADY WIND FORCE 8?

    Oct 1, 2018, 00:00

  • PIN19 - A COST COMPARISON OF TREATING CHRONIC HEPATITIS C PATIENTS WITH SOFOSBUVIR-BASED REGIMENS

    Oct 1, 2018, 00:00

  • PSY81 - DIRECT COSTS ASSOCIATED WITH THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RELAPSED OR REFRACTORY IN ARGENTINA

    Oct 1, 2018, 00:00

  • PMS98 - EFFECTIVENESS OF FALL PREVENTION PROGRAM IN PATIENTS WITH OSTEOPOROSIS

    Oct 1, 2018, 00:00

  • PMD29 - BUDGET IMPACT ANALYIS OF MECHANICHAL THROMBECTOMY IN THE TREATMENT OF ACUTE ISCHEMUC STROKE

    Oct 1, 2018, 00:00

  • PHP76 - ANALYSIS OF APPROVAL TIMING FOR 89 NEW DRUGS IN ITALY FROM JANUARY 2015 TO MAY 2018

    Oct 1, 2018, 00:00

  • PMH18 - MARKOV MODEL FOR PREDICTING THE RISK OF DEVELOPING DEMENTIA IN ELDERLY ADULTS

    Oct 1, 2018, 00:00

  • PDB96 - APPLYING MCDA FRAMEWORK IN PHARMACEUTICAL POLICY DECISION MAKING- A PILOT STUDY IN DIABETES MELLITUS TYPE 2

    Oct 1, 2018, 00:00

  • PCN316 - RELATIONSHIP BETWEEN TWO CANCER CLINICAL BENEFIT FRAMEWORKS AND HEALTH TECHNOLOGY DECISIONS IN THREE EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PCN96 - INITIAL THERAPY FOR ADVANCED PROSTATE CARCINOMA (PCA) WITH A GNRH AGONIST (GNRHA) AND ANTAGONISTS - A RETROSPECTIVE ANALYSIS OF PRESCRIPTION PATTERNS AND HOSPITAL COSTS BASED ON GERMAN GKV [GESETZLICHE KRANKENVERSICHERUNG (STATUTORY ...

    Oct 1, 2018, 00:00

  • PHP38 - ENZYME REPLACEMENT THERAPIES WITHIN THE GERMAN HTA (AMNOG) PROCESS

    Oct 1, 2018, 00:00

  • PRS56 - COST-EFFECTIVENESS OF AMBULATORY OXYGEN IN IMPROVING QUALITY OF LIFE IN FIBROTIC LUNG DISEASE- A TALE OF TWO OUTCOMES

    Oct 1, 2018, 00:00

  • PCP44 - IMPLICATIONS OF GENOME-DRIVEN ONCOLOGY ON EVIDENCE REQUIREMENTS FOR HEALTH TECHNOLOGY ASSESSMENT

    Oct 1, 2018, 00:00

  • PSS73 - IMPACT OF CENEGERMIN ON THE QUALITY OF LIFE IN NEUROTROPHIC KERATOPATHY

    Oct 1, 2018, 00:00

  • PMD100 - ECONOMIC EVALUATION OF PROTHROMBIN TIME TEST STRIPS (COAGUCHEK PRO II)

    Oct 1, 2018, 00:00

  • PRM29 - COMPARING OPTHALMOLOGY TREATMENTS VIA THE INTEGRATION OF IPD AND AGGREGATE-LEVEL DATA- WHICH MATCHING ADJUSTED INDIRECT COMPARISON (MAIC) APPROACH IS BEST?

    Oct 1, 2018, 00:00

  • PRM212 - PATIENT EXPERIENCE WITH PLATINUM-RESISTANT OR PLATINUM-REFRACTORY OVARIAN CANCER

    Oct 1, 2018, 00:00

  • PMS62 - COST-EFFECTIVENESS OF REDUCING ARTHRITIS FATIGUE BY CLINICAL TEAMS (RAFT) USING COGNITIVE–BEHAVIOURAL APPROACHES- A RANDOMISED CONTROLLED TRIAL

    Oct 1, 2018, 00:00

  • PMU15 - ANALYSIS OF THE METHODOLOGICAL OBJECTIONS REGARDING INDIRECT TREATMENT COMPARISON SUBMITTED TO THE HAUTE AUTORITÉ DE SANTÉ (HAS)

    Oct 1, 2018, 00:00

  • PHP324 - NICE- A MULTIPROGRAM HTA ORGANIZATION TO SUIT ALL?

    Oct 1, 2018, 00:00

  • PCN107 - BURDEN AND COSTS OF ACUTE MYELOID LEUKAEMIA IN PORTUGAL

    Oct 1, 2018, 00:00

  • PCV16 - A SYSTEMATIC REVIEW ON THE EFFICACY OF PHARMACOLOGICAL TREATMENTS IN PATIENTS WITH HEART FAILURE (HF) WITH PRESERVED EJECTION FRACTION (HFPEF)

    Oct 1, 2018, 00:00

  • PCV53 - IS EDOXABAN MORE COST-EFFECTIVE THAN WARFARIN IN PREVENTION OF STROKE AND DEEP VEIN THROMBOSIS?

    Oct 1, 2018, 00:00

  • PCN189 - ANALYSIS COST / UTILITY OF THE THERAPEUTIC THERAPY TREATMENT OF LUNG CANCER IN A UNIVERSITY HOSPITAL OF SPAIN

    Oct 1, 2018, 00:00

  • MO2 - MODELLING OVERALL SURVIVAL IN IMMUNOTHERAPY USING PARAMETRIC TECHNIQUES- AVELUMAB IN PREVIOUSLY TREATED METASTATIC MERKEL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PGI51 - PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) REPORT HIGHER ECONOMIC BURDEN THAN CONTROLS- RESULTS FROM THE EU5 NATIONAL HEALTH AND WELLNESS SURVEY

    Oct 1, 2018, 00:00

  • PSS13 - BUDGET IMPACT ANALYSIS OF APREMILAST IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS IN GREECE

    Oct 1, 2018, 00:00

  • PCP47 - TAMING THE TORNADO CHART- SIMPLIFYING ONE-WAY SENSITIVITY ANALYSES FOR LARGE-SCALE MULTI-PARAMETER MODELS

    Oct 1, 2018, 00:00

  • PIN110 - COMPARISON OF DRUG ASSESSMENT REPORTS PUBLISHED BY FRENCH (HAS-CEESP) AND UK (NICE) HTAS- FOCUS ON HEPATITIS C

    Oct 1, 2018, 00:00

  • PMH54 - PATTERNS OF LONG-TERM CUSTODIAL CARE IN PARKINSON DISEASE PSYCHOSIS

    Oct 1, 2018, 00:00

  • PCN84 - TOTAL COST OF CARE AND BUDGET IMPACT FOR PATIENTS WITH CLL TREATED WITH VENETOCLAX

    Oct 1, 2018, 00:00

  • PP4 - ONE SIZE DOES NOT FIT ALL- HETEROGENEOUS PATIENT PREFERENCES AND TRADEOFFS FOR ANTIRETROVIRAL THERAPY - RESULTS OF A DISCRETE CHOICE EXPERIMENT

    Oct 1, 2018, 00:00

  • PCV108 - PRESCRIBING CHOICE AND THE COST OF ANTICOAGULATION IN ATRIAL FIBRILLATION- A REAL WORLD STUDY COMPARING HEALTHCARE EXPENDITURE WITH WARFARIN AND APIXABAN

    Oct 1, 2018, 00:00

  • PMS2 - RETROSPECTIVE STUDY TO EVALUATE OSTEOARTHRITIS POPULATION IN GERMANY AND IDENTIFY INFLUENTIAL FACTORS IN FAST, MEDIUM AND SLOW PROGRESSING PATIENTS

    Oct 1, 2018, 00:00

  • PDB52 - ANNUAL COST OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TURKEY

    Oct 1, 2018, 00:00

  • PSY107 - COST-EFFECTIVENESS OF BUDESONIDE IN MICROSCOPIC COLITIS PATIENTS IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PHP74 - A REVIEW OF THE INFLUENCE OF INTERNATIONAL REFERENCE PRICING (IRP) ON LAUNCH SEQUENCING IN EUROPE

    Oct 1, 2018, 00:00

  • PRM134 - USING ADJUSTED INDIRECT COMPARISON IN HTA TO OVERCOME SHORT FOLLOW-UP TIME IN REGULATORY RANDOMIZED CONTROLED CLINICAL TRIALS- RIBOCICLIB AS FIRST-LINE THERAPY FOR HR-POSITIVE, ADVANCED BREAST CANCER

    Oct 1, 2018, 00:00

  • PDB14 - MOBILE APPS FOR MEDICATION ADHERENCE IN DIABETES

    Oct 1, 2018, 00:00

  • PHP249 - ARE TRADITIONAL MANAGED ENTRY AGREEMENTS SUITABLE FOR POTENTIALLY, CURATIVE GENE/CELL THERAPIES?

    Oct 1, 2018, 00:00

  • PCN89 - COST –EFFECTIVENESS ANALYSIS OF PERTUZUMAB AS FIRST LINE NEOADJUVANT TREATMENT OPTION FOR PATIENTS HER2 + BREAST CANCER IN REPUBLIC OF MACEDONIA

    Oct 1, 2018, 00:00

  • PSS20 - ECONOMIC BURDEN OF PSORIASIS (PSO) IN TURKEY

    Oct 1, 2018, 00:00

  • PSY31 - COMPARISON OF THE ESTIMATED PREVALENCE OF DIAGNOSED HOMOCYSTINURIA AND PHENYLKETONURIA IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PMD14 - PDL1 TESTING PATTERNS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER IN ISRAEL - AN ANALYSIS OF REAL WORLD DATA

    Oct 1, 2018, 00:00

  • PRM33 - HUMAN CAPITAL VS. FRICTION COST APPROACH – DIFFERENCES IN THE PRESENCE OF DEATH AND LONG-TERM CONSEQUENCES

    Oct 1, 2018, 00:00

  • RM4 - EXPLORING TIME-DEPENDENT VARIATION OF PATIENT-REPORTED OUTCOME SCORES ACROSS DIFFERENT TIME-POINTS FOR PATIENTS WITH MULTIPLE CONDITIONS- A MIXED METHODS LONGITUDINAL STUDY

    Oct 1, 2018, 00:00

  • PMD174 - IMPACT OF MEDICAL DEVICE REGULATION ON FUTURE HTA’S AND REIMBURSEMENT DECISIONS IN GERMANY, FRANCE AND SWITZERLAND – WHAT IS BLOOMING HERE?

    Oct 1, 2018, 00:00

  • PCN1 - REAL-WORLD EFFECTIVENESS AND TOLERABILITY OF SMALL-CELL LUNG CANCER (SCLC) TREATMENTS- A SYSTEMATIC LITERATURE REVIEW (SLR)

    Oct 1, 2018, 00:00

  • PCV152 - TREATMENT BURDEN ASSOCIATED WITH DIFFERENT ANTICOAGULATION STRATEGIES OF ATRIAL FIBRILLATION PATIENTS- AN OBSERVATIONAL STUDY IN GERMANY, SWEDEN AND SWITZERLAND BASED ON THE ANTI-CLOT TREATMENT SCALE

    Oct 1, 2018, 00:00

  • PCN141 - COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA IN GREECE

    Oct 1, 2018, 00:00

  • PRM191 - LONGITUDINAL CONSTRUCT VALIDITY OF THE HEMOPHILIA CAREGIVER IMPACT MEASURE

    Oct 1, 2018, 00:00

  • PCN105 - ECONOMIC BURDEN OF RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN FRANCE

    Oct 1, 2018, 00:00

  • PCN56 - TREATMENT EFFECT MODIFICATION (EM) OF ANTICANCER THERAPIES IN FIRST-LINE ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)- A SYSTEMATIC ASSESSMENT OF TRIAL DATA

    Oct 1, 2018, 00:00

  • PHP1 - EXPECTED DEMAND FOR HEALTH SERVICES FROM A VOLUNTARY INSURER

    Oct 1, 2018, 00:00

  • PSY171 - EXPECTED AND ACTUAL REIMBURSEMENT BASED ON CLINICAL PRACTICE GUIDELINE RECOMMENDATIONS IN TURKEY

    Oct 1, 2018, 00:00

  • PHP174 - ARE FIXED THERAPEUTIC-LEVEL SPENDING CAPS ADVISABLE FOR THE GREEK OUTPATIENT MARKET? METHODOLOGICAL ISSUES AND HEALTH POLICY PROPOSALS

    Oct 1, 2018, 00:00

  • PRM70 - NON-SMALL CELL LUNG CANCER MARKET ANALYSIS FOR TARGETED THERAPIES IN TURKEY

    Oct 1, 2018, 00:00

  • PDB47 - THE ASSOCIATION BETWEEN RENAL FUNCTION AND HEALTHCARE COSTS IN US PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PHP216 - HOW RESPONSIVE IS INDUSTRY TO VALUE BASED PROCUREMENT (VBP)?

    Oct 1, 2018, 00:00

  • PIH29 - DEVELOPMENT OF A DECISION AID PROTOTYPE FOR PARENTS CONSIDERING TUBE FEEDING FOR THEIR CHILDREN

    Oct 1, 2018, 00:00

  • PND25 - ECONOMIC ANALYSIS OF COMPREHENSIVE REHABILITATION EFFICIENCY WITH AND WITHOUT BOTULINUM NEUROTOXIN A INJECTIONS IN CHILDREN WITH SPASTIC CEREBRAL PALSY

    Oct 1, 2018, 00:00

  • PSS7 - QUALITY OF LIFE IMPROVEMENTS IN PSORIASIS WITH SECUKINUMAB IN A DIFFICULT TO TREAT POPULATION OF ANTI-TNF ALPHA FAILURE PATIENTS FROM THE UK AND REPUBLIC OF IRELAND

    Oct 1, 2018, 00:00

  • PCN390 - METASTATIC COLORECTAL CANCER (MCRC) - LITERATURE REVIEW ON QUALITY OF LIFE INSTRUMENTS

    Oct 1, 2018, 00:00

  • PMH17 - PREDICTING RECURRENCE OF DEPRESSION USING LIFELOG DATA- A PANEL VAR APPROACH

    Oct 1, 2018, 00:00

  • PND111 - ELICITING PREFERENCES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS – A BRAZILIAN STUDY USING A MULTICRITERIA DECISION ANALYSIS (MCDA) APPROACH

    Oct 1, 2018, 00:00

  • PCN258 - HEALTHCARE RESOURCE UTILISATION (HCRU) AMONG PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN- THE SCAN-LEAF STUDY

    Oct 1, 2018, 00:00

  • HT7 - A REVIEW OF EFFICIENCY OPINIONS OF FRENCH ‘HAUTE AUTORITE DE SANTE’ (HAS) IN THE ONCOLOGY FIELD

    Oct 1, 2018, 00:00

  • PCN275 - HOW DO HTA DECISIONS FOR NEW DISEASE CONDITIONS IMPACT TIME TO PRICE CHANGES?

    Oct 1, 2018, 00:00

  • PMU56 - ECONOMIC EVALUATION OF POSACONAZOLE IN COMPARISON WITH LIPOSOMAL AMPHOTERICIN B IN THE TREATMENT OF MUCORMYCOSIS IN IRAN

    Oct 1, 2018, 00:00

  • PRM6 - INCREASED RISK OF CUTANEOUS ADVERSE DRUG REACTION AMONG OLDER ADULTS EXPOSED TO POLYPHARMACY

    Oct 1, 2018, 00:00

  • PMD170 - A RESEARCH ON HOSPITAL BASED-HEALTH TECHNOLOGY ASSESSMENT MODELS OF ACQUISITION OF MEDICAL DEVICES IN HOSPITALS- THE CASE OF TURKEY

    Oct 1, 2018, 00:00

  • PRM98 - FACTORS ASSOCIATED WITH THE INCIDENCE OF ONCOLOGY DRUGS SHORTAGES IN THE UNITED STATES (2001-2017)

    Oct 1, 2018, 00:00

  • PRM241 - AN OUT-OF-SAMPLE METHOD TO QUANTIFY SYSTEMATIC ERROR IN UNANCHORED INDIRECT COMPARISONS

    Oct 1, 2018, 00:00

  • PDB74 - IDEGLIRA VERSUS IGLARLIXI FOR PATIENTS WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN- A LONG-TERM COST-EFFECTIVENESS ANALYSIS IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PCV20 - NUMBER NEEDED TO TREAT FOR ORAL ANTI-COAGULANTS VERSUS VKA IN STROKE PREVENTION IN ATRIAL FIBRILLATION

    Oct 1, 2018, 00:00

  • PND67 - ARE NEW PREVENTIVE MIGRAINE DRUGS COST-EFFECTIVE FOR PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE FOR WHOM OTHER PREVENTIVE MEDICATIONS HAD FAILED?

    Oct 1, 2018, 00:00

  • PSY105 - COST-UTILITY OF NINTEDANIB VERSUS PIRFENIDONE FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS- A BELGIAN PERSPECTIVE

    Oct 1, 2018, 00:00

  • PSY49 - BUDGETARY IMPACT OF ORPHAN DRUGS IN THE CATALAN HEALTHCARE SERVICE

    Oct 1, 2018, 00:00

  • PCN229 - COMPARISON OF SICKNESS BENEFIT AND SICK LEAVE DURATION IN ONCOLOGY ACROSS COUNTRIES

    Oct 1, 2018, 00:00

  • PIN44 - ECONOMIC EVALUATION OF 60+ YEARS ADULT VACCINATION STRATEGY USING PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN SPAIN

    Oct 1, 2018, 00:00

  • PND142 - FRENCH DATA FROM A WORLDWIDE PATIENT SURVEY ON ECONOMIC IMPACT OF MIGRAINE

    Oct 1, 2018, 00:00

  • PCN64 - REVIEW OF NICE HTA SUBMISSIONS INCLUDING METHODOLOGIES ADJUSTING FOR OVERALL SURVIVAL IN THE PRESENCE OF TREATMENT SWITCHING

    Oct 1, 2018, 00:00

  • PMD2 - STUDY OF STATINS EFFECTS ON COGNITIVE IMPAIRMENT AMONG OUTPATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PCN124 - DIRECT COST OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) FOR RELAPSED/REFRACTORY (RR) DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS FROM THE FRENCH HOSPITAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • PRM39 - IS THE CHOICE OF WILLINGNESS-TO-PAY THRESHOLD IN COST-UTILITY ANALYSIS ENDOGENOUS TO THE RESULTING VALUE OF THE TECHNOLOGY?

    Oct 1, 2018, 00:00

  • PCN70 - ASSESSING THE BUDGET IMPACT OF INCLUDING SUNITINIB FOR THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ARGENTINA

    Oct 1, 2018, 00:00

  • PND110 - GENE THERAPY PRODUCTS – MARKET ACCESS SITUATION IN EU AND IN SLOVAKIA

    Oct 1, 2018, 00:00

  • ND3 - META-ANALYSIS OF REAL-WORLD ADHERENCE AND PERSISTENCE OF MAINTENANCE ONCE- OR TWICE-DAILY ORAL DISEASE-MODIFYING DRUGS (DIMETHYL FUMARATE, FINGOLIMOD, AND TERIFLUNOMIDE) IN MULTIPLE SCLEROSIS

    Oct 1, 2018, 00:00

  • PMU53 - HOSPITAL COSTS OF SPINAL LUMBAR FUSION SURGERIES WITH NEUROMONITORING

    Oct 1, 2018, 00:00

  • PSY148 - PRIMARY NON-ADHERENCE AMONG NEWLY DIAGNOSED RHEUMATOID ARTHRITIS PATIENTS

    Oct 1, 2018, 00:00

  • PCN103 - PREDICTED TREATMENT COSTS AND SAVINGS PER PATIENT OF KANJINTI® (TRASTUZUMAB BIOSIMILAR) VS. SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) HERCEPTIN® AND OTHER TRASTUZUMAB BIOSIMILARS IN ITALY

    Oct 1, 2018, 00:00

  • PSS33 - SECUKINUMAB AS FIRST BIOLOGIC TREATMENT- A COST PER RESPONDER ANALYSIS COMPARED WITH LICENSED BIOLOGICS, FOR MODERATE TO SEVERE PSORIASIS IN ARGENTINA

    Oct 1, 2018, 00:00

  • PHP323 - ESTABLISHING AN ALIGNED VIEW OF MODERN, FORWARD-LOOKING HTA PROCESS

    Oct 1, 2018, 00:00

  • PCN153 - COST-EFFECTIVENESS ANALYSIS OF APALUTAMIDE FOR TREATMENT IN NON- METASTASIS CASTRATION-RESISTANT PROSTATE CANCER

    Oct 1, 2018, 00:00

  • PCN7 - A TIME WITHOUT SYMPTOMS OR TOXICITY ANALYSIS OF NIRAPARIB COMPARED WITH ROUTINE SURVEILLANCE IN THE MAINTENANCE TREATMENT OF PATIENTS WITH RECURRENT OVARIAN CANCER

    Oct 1, 2018, 00:00

  • PCN147 - COST-EFFECTIVENESS SIMULATION AND ANALYSIS OF COLORECTAL CANCER SCREENING IN SHANGHAI POPULATION, CHINA- COMPARISON BETWEEN URBAN AND RURAL RESIDENTS

    Oct 1, 2018, 00:00

  • PHP77 - EFFECT OF NEW INDICATIONS ON THE PRICE DEVELOPMENT OF NEW MEDICINAL PRODUCTS IN GERMANY

    Oct 1, 2018, 00:00

  • PSY80 - THE COST OF HEALTHCARE FOR CHILDREN WITH SICKLE CELL DISEASE- AN ANALYSIS OF HEALTHCARE UTILIZATION AND EXPENDITURES IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PCP4 - DEVELOMENT OF A QUALITY MANAGEMENT SYSTEM FOR EUNETHTA AND THE PERMANENT EUROPEAN COLLABORATION ON HTA

    Oct 1, 2018, 00:00

  • MD4 - DIGITAL HEALTHCARE EVALUATION AT NICE- AN EVOLVING PROCESS

    Oct 1, 2018, 00:00

  • PMS97 - THE EFFECT OF NEUROMUSCULAR AND NEUROMUSCULAR-CORE TRAINING ON INJURY PREVENTION

    Oct 1, 2018, 00:00

  • PCV75 - AN UPDATED COST-EFFECTIVENESS PAIRWISE ANALYSIS OF APIXABAN AND WARFARIN FOR STROKE PREVENTION IN PATIENTS WITH NON- VALVULAR ATRIAL FIBRILLATION IN FRANCE

    Oct 1, 2018, 00:00

  • PCN135 - DOES PATIENT SELECTION CRITERIA TRANSLATE INTO COST SAVINGS IN PATIENTS WITH ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AFTER CHEMOTHERAPY FAILURE IN SPAIN?

    Oct 1, 2018, 00:00

  • PSY154 - ECONOMIC BURDEN OF BETA-THALASSEMIA- LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PSS59 - CLINICAL CHARACTERISTICS OF BIOLOGIC ELIGIBLE HIDRADENITIS SUPPURATIVA PATIENTS IN EU5

    Oct 1, 2018, 00:00

  • CN2 - PREDICTING UTILITY SCORES IN LOCALIZED PROSTATE CANCER- MAPPING FROM EPIC TO PORPUS

    Oct 1, 2018, 00:00

  • PMD68 - A COST-CONSEQUENCE ANALYSIS OF ANACONDA VERSUS PROPOFOL AND MIDAZOLAM IN THE LONG-TERM SEDATION OF CRITICALLY-ILL SURGICAL PATIENTS FROM THE UK NHS PERSPECTIVE

    Oct 1, 2018, 00:00

  • PSY195 - HUMANISTIC BURDEN ASSOCIATED WITH RPE65 GENE MUTATION RELATED INHERITED RETINAL DYSTROPHIES- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCP67 - REGULATORY REQUIREMENTS AND SCIENTIFIC RATIONALE FOR BIOSIMILAR- US VS. EUROPEAN UNION.

    Oct 1, 2018, 00:00

  • PMD31 - THE CONCORDANCE AND BUDGET IMPACT OF MULTIPLE ER, PR AND HER2 DETERMINATIONS IN DUTCH BREAST CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PCP45 - THE ROLE OF CROSSOVER AND TREATMENT SWITCHING IN INDIRECT TREATMENT COMPARSON IN IMMUNO-ONCOLOGY

    Oct 1, 2018, 00:00

  • PCV155 - EVALUATING THE IMPACT OF PHARMACIST INTERVENTION ON DISEASE KNOWLEDGE, ILLNESS PERCEPTIONS, AND BELIEF TOWARDS MEDICATIONS IN ACUTE CORONARY SYNDROME PATIENTS IN HONG KONG

    Oct 1, 2018, 00:00

  • PMS49 - COST-EFFECTIVENESS OF FRACTURE PREVENTION PROVIDED TO ELDERLY LIVING IN THE COMMUNITY

    Oct 1, 2018, 00:00

  • PRM232 - LONGITUDINAL MATCHING- A METHOD FOR GENERATING COMPARABLE SAMPLES OF TREATED AND TREATMENT-NAÏVE PATIENTS WITH PROGRESSIVE CONDITIONS

    Oct 1, 2018, 00:00

  • PHP271 - THE GROWING IMPORTANCE OF DIGITAL CHANNELS IN FORMULARY DECISION MAKING IN THE US

    Oct 1, 2018, 00:00

  • PRM271 - REDUCING LENGTH OF AN OUTCOMES-BASED CONTRACT THROUGH ACTIVE-LEARNING BY PAYERS

    Oct 1, 2018, 00:00

  • PHP148 - SELF-PERCEIVED HEALTH INEQUALITIES BY INCOME DISTRIBUTION IN EUROPEAN UNION

    Oct 1, 2018, 00:00

  • PCN384 - HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ADVANCED (STAGE II-IV) OVARIAN CANCER RESISTANT OR REFRACTORY TO FRONTLINE PLATINUM-BASED THERAPY

    Oct 1, 2018, 00:00

  • PUK15 - PHARMACOECONOMICS MODES OF ANTIBIOTIC THERAPYOF UNCOMPLICATED COMMUNITY-ACQUIRED ACUTE PYELONEPHRITIS IN A MULTIDISCIPLINARY HOSPITALS

    Oct 1, 2018, 00:00

  • PRS8 - EFFECTS OF SMOKIMG CESSATION ON HEALTH OUTCOMES AMONG COPD PATIENTS IN SOUTH KOREA- 12 YEARS FOLLOW-UP

    Oct 1, 2018, 00:00

  • CN8 - COST-EFFECTIVENESS ANALYSIS OF ORAL CANCER SCREENING IN TAIWAN- A REAL WORLD DATA ANALYSIS

    Oct 1, 2018, 00:00

  • PDB94 - INITIAL ANTIDIABETIC PHARMACOTHERAPY PRESCRIBED TO PATIENTS WITH NEWLY DIAGNOSED TYPE-2 DIABETES IN A COMMERCIAL HEALTH PLAN IN THE UNITED STATED

    Oct 1, 2018, 00:00

  • MD1 - EVIDENCE DEVELOPMENT TIMELINE OF MEDICAL DEVICES IN THE UK- WHERE DO MEDICAL INNOVATION BRIEFINGS FIT?

    Oct 1, 2018, 00:00

  • PDB17 - REAL-WORLD DOSING BEHAVIOURS AND OUTCOMES WHEN SWITCHING TO IDEGLIRA FROM A FREE COMBINATION OF INSULIN AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY

    Oct 1, 2018, 00:00

  • PCN352 - UTILITY VALUES FOR ADVANCED HEPATOCELLULAR CARCINOMA PATIENTS IN FRANCE RECEIVING SELECTIVE INTERNAL RADIATION THERAPY (SIRT) WITH Y-90 RESIN MICROSPHERES VERSUS SORAFENIB USING EQ-5D SCORES MAPPED FROM EORTC-QLQ-C30 RESULTS

    Oct 1, 2018, 00:00

  • PCN377 - RESPONSE SHIFT EFFECT ON QUALITY OF LIFE IN RANDOMIZED CONTROL TRIAL OF TAXANE VERSUS S-1 FOR METASTATIC BREAST CANCER PATIENTS (SELECT-BC)- STRUCTURAL EQUATION MODELING

    Oct 1, 2018, 00:00

  • PHP342 - HOW TO MAXIMIZE THE EX-FACTORY PRICE IN PORTUGAL, WITH SIMULTANEOUS BENEFITS FOR PATIENTS AND PAYERS – AN INDUSTRY PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCN356 - HOW SHOULD WE VALIDATE UTILITY MAPPING ALGORITHMS BEFORE USE? AN EXAMPLE IN NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • Researchers, Patients, and Stakeholders Evaluating Comparative-Effectiveness Research- A Mixed-Methods Study of the PCORI Reviewer Experience

    Oct 1, 2018, 00:00

  • PRS97 - PATIENT REPORTED OUTCOMES IN COPD CLINICAL TRIALS- TRENDS AND GAPS

    Oct 1, 2018, 00:00

  • PRM180 - COMPARING QALYS GENERATED FOR THE EQ-5D-3L AND EQ-5D-5L IN A LONGITUDINAL STUDY OF CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PHP303 - WHAT ARE THE KEY CONSIDERATIONS FOR SEEKING PAYER SCIENTIFIC ADVICE IN THE EU?

    Oct 1, 2018, 00:00

  • PCP6 - HOW TO INTRODUCE MULTI-INDICATION BASED PRICING IN FINLAND?

    Oct 1, 2018, 00:00

  • PDB78 - ECONOMIC EVALUATION OF DAPAGLIFLOZIN AS ADD-ON TO METFORMIN FOR T2DM TREATMENT IN THE ISRAELI HEALTHCARE SETTING

    Oct 1, 2018, 00:00

  • PCN83 - THE USE OF OBINUTUZUMAB IN TREATMENT OF REFRACTORY AND RELAPSING FOLLICULAR LYMPHOMA

    Oct 1, 2018, 00:00

  • PMD25 - RISK FACTORS ASSOCIATED WITH PCO FOLLOWING CATARACT SURGERY- REAL-WORLD OUTCOMES STUDY IN THE UNITED KINGDOM (UK)

    Oct 1, 2018, 00:00

  • PCN301 - HEALTH TECHNOLOGY ASSESSMENT FOR CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR CANCER

    Oct 1, 2018, 00:00

  • PCV31 - ANTICOAGULANTS IN OLDER PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION AFTER INTRACRANIAL HEMORRHAGE

    Oct 1, 2018, 00:00

  • PIN115 - BARRIERS TO ACCESS AND IMPLEMENTATION OF ROTAVIRUS VACCINATION IN EUROPE

    Oct 1, 2018, 00:00

  • PHP268 - THE HUNGARIAN PALLIATIVE CARE POSITION, CHALLENGES, BREAK POINTS

    Oct 1, 2018, 00:00

  • PMS89 - DEVELOPMENT OF AN OUTCOMES MEASUREMENT TOOL TO EVALUATE THE QUALITY OF BIOLOGIC SWITCH IN PSORIATIC ARTHRITIS

    Oct 1, 2018, 00:00

  • PDB58 - REIMBURSEMENT FOR TYPE 2 DIABETES MELLITUS PATIENTS HOSPITALIZED IN A MUNICIPAL HOSPITAL IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PGI47 - OPIOID USAGE AND PATIENT-REPORTED PAIN SCORES IN IRRITABLE BOWEL SYNDROME PATIENTS- A RETROSPECTIVE ANALYSIS OF A LARGE U.S. ELECTRONIC HEALTH RECORD DATABASE

    Oct 1, 2018, 00:00

  • PRM125 - SYSTEMATIC REVIEW OF META-MODELING APPLICATIONS AND OPPORTUNITIES FOR ADVANCED ANALYSES WITH HEALTH ECONOMIC MODELS

    Oct 1, 2018, 00:00

  • PMU42 - ECONOMIC AND ORGANIZATIONAL IMPACT OF A VASCULAR ACCESS TEAM IN AN ITALIAN HOSPITAL

    Oct 1, 2018, 00:00

  • PCN120 - EPIDEMIOLOGY AND COSTS OF NON-SMALL CELL LUNG CANCER (NSCLC) IN AUSTRIA

    Oct 1, 2018, 00:00

  • PSY64 - BLEEDING EPISODES, THE MOST IMPACTFUL VARIABLE IN THE TREATMENT COST OF THE HEMOPHILIA A IN COLOMBIA. DATA FROM THE LITERATURE AND THE REAL LIFE

    Oct 1, 2018, 00:00

  • PRM157 - THE IMPACT OF LANDMARK RESPONSE ON OVERALL SURVIVAL- IMPLICATIONS FOR THE ECONOMIC EVALUATION OF IMMUNE-THERAPY (I-O) TREATMENT IN SMALL CELL LUNG CANCER (SCLC)

    Oct 1, 2018, 00:00

  • PMD38 - CELL-FREE FETAL DNA AS A CONTINGENT PRENATAL SCREENING OF TRISOMIES CONDITIONAL TO A RISK ≥ 1-1,000 FOR ITALIAN PREGNANT WOMEN- AN ECONOMIC EVALUATION

    Oct 1, 2018, 00:00

  • PMH49 - LAUNCHING LONG ACTING PRODUCTS TO TREAT OPIOID USE DISORDER- ARE PAYERS WILLING TO PAY PREMIUM PRICE?

    Oct 1, 2018, 00:00

  • PSY46 - A DYNAMIC APPROACH FOR BUDGET IMPACT ANALYSIS (BIA) IN ONCOLOGY – THE CASE OF NOVEL TREATMENT COMBINATIONS FOR FRONTLINE TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TIE NDMM)

    Oct 1, 2018, 00:00

  • PSS43 - DUPILUMAB IMPROVES ABSENTEEISM IN MODERATE-TO-SEVERE ATOPIC DERMATITIS PATIENTS COMPARED WITH PLACEBO IN PHASE 3 LIBERTY AD SOLO STUDIES

    Oct 1, 2018, 00:00

  • PCN191 - COST-EFFECTIVENESS OF MONITORING ENDOXIFEN LEVELS IN BREAST CANCER PATIENTS ADJUVANTLY TREATED WITH TAMOXIFEN

    Oct 1, 2018, 00:00

  • PHP336 - THE PRESCRIPTION COST ANALYSIS AS A TOOL TO INFORM HEALTHCARE RESOURCE ALLOCATION AND ACCESS TO PHARMACEUTICALS IN ENGLAND

    Oct 1, 2018, 00:00

  • PMH39 - HEALTH-ECONOMIC EVALUATION OF PHARMACOGENETIC TESTS IN PSYCHIATRIC IN-PATIENT CARE

    Oct 1, 2018, 00:00

  • PCN72 - BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN ENGLAND

    Oct 1, 2018, 00:00

  • PCN325 - COMPARING THE ROLE OF DIFFERENT SPECIALITIES IN THE MANAGEMENT OF PROSTATE CANCER IN FRANCE AND ITALY- INSIGHTS FROM A REAL-WORLD STUDY

    Oct 1, 2018, 00:00

  • PIN11 - HPV9-RELATED DISEASES- THE ECONOMIC BURDEN ON THE SOCIAL SECURITY SYSTEM IN ITALY

    Oct 1, 2018, 00:00

  • PRM4 - A CASE STUDY IN CHOOSING WISELY RECOMMENDATION ADOPTION- SINGLE FRACTION RADIATION TREATMENT OF BONE METASTASES

    Oct 1, 2018, 00:00

  • PGI24 - COST-UTILITY ANALYSIS OF VITAMINE E AND PIOGLITAZONE IN ADDITION TO 2 YEARS OF LIFE-STYLE MODIFICATION THERAPY FOR NON-ALCOHOLIC STEATOHEPATITIS PATIENTS IN JAPAN

    Oct 1, 2018, 00:00

  • PSY85 - ECONOMIC BURDEN ASSOCIATED WITH RPE65 GENE RELATED INHERITED RETINAL DYSTROPHIES- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PND117 - PHYSICIAN REPORTED ADHERENCE IN MS PATIENTS TREATED WITH INJECTABLE PLATFORM THERAPIES VERSUS DELAYED-RELEASE DIMETHYL FUMARATE- FINDINGS FROM A REAL-WORLD CROSS-SECTIONAL STUDY

    Oct 1, 2018, 00:00

  • PSY70 - MANAGEMENT COSTS OF CHEMOTHERAPY AND ALLOGENEIC STEM-CELL TRANSPLANT OF CHILDREN AND ADOLESCENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN FRANCE

    Oct 1, 2018, 00:00

  • PMH14 - SOCIAL FUNCTIONING AT ADMISSION IN PATIENTS WITH MENTAL ILLNESS HOSPITALIZED COMPULSORILY BY PREFECTURAL GOVERNORS IN ACCORDANCE WITH THE PROVISIONS OF ARTICLE 29 OF THE JAPANESE MENTAL HEALTH ACT.

    Oct 1, 2018, 00:00

  • PHP257 - AN ANALYSIS AND FEASIBILITY ASSESSMENT OF INDICATION-SPECIFIC PRICING AS A MEANS TO IMPROVE PATIENT ACCESS TO MEDICINES AND REINFORCE INCENTIVES FOR INNOVATION

    Oct 1, 2018, 00:00

  • PCP61 - EVIDENCE-BASED VALUE OF PD-1 / PD-L1 INHIBITORS IN NSCLC- COMPARISON OF VALUE TO PRICE

    Oct 1, 2018, 00:00

  • PHP261 - IMPACT OF DYNAMIC CHANGES OF THE DEFINITION OF THE APPROPRIATE COMPARATIVE THERAPY (ACT) ON MARKET ACCESS PERFORMANCE OF NEW ACTIVE SUBSTANCES IN GERMANY

    Oct 1, 2018, 00:00

  • PCN270 - HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH 6 PREVALENT CANCER IN SPAIN, A REALWORLD DATA STUDY

    Oct 1, 2018, 00:00

  • PRS58 - PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)- WHAT HAPPENS BEFORE THE DIAGNOSIS? A REAL-WORLD, RETROSPECTIVE, PRIMARY CARE DATABASE ANALYSIS

    Oct 1, 2018, 00:00

  • PMD30 - BUDGET IMPACT ANALYSIS OF ROUTINE ADOPTION OF NON-INVASIVE PRENATAL TESTING (NIPT) IN DIFFERENT RISK-SCORE PREGNANCY POPULATIONS IN THE UK

    Oct 1, 2018, 00:00

  • PHP321 - THE HTA APPROACH OF NOVEL TREATMENTS IN THE CENTRAL EASTERN EUROPEAN COUNTRY FOR FIVE YEARS PERIOD (2013-2017)- THE CASE OF BULGARIA

    Oct 1, 2018, 00:00

  • PHP243 - DO DISEASE SEVERITY AND/OR QUALITY OF CLINICAL DATA INFLUENCE PRICING POLICY IN FRANCE? AN ANALYSIS ON ORPHAN DRUGS AND BLOOD CANCERS TREATMENTS

    Oct 1, 2018, 00:00

  • PRM9 - A LONGITUDINAL, ITEM-LEVEL ANALYSIS METHODOLOGY TO SUPPORT THE INTERPRETABILITY OF MULTI-ITEM PATIENT-REPORTED OUTCOMES

    Oct 1, 2018, 00:00

  • PMD155 - IMPACT OF MINIMALLY INVASIVE TREATMENTS FOR PERIPHERAL ARTERIAL DISEASE IN HUNGARY

    Oct 1, 2018, 00:00

  • PCN320 - RECOMMENDATIONS OF SPANISH THERAPEUTIC POSITIONING REPORTS FOR NEW ONCOLOGY DRUGS SINCE YEAR 2013

    Oct 1, 2018, 00:00

  • PRM102 - ANALYZING REAL-WORLD DATA TO TARGET HARD-TO-IDENTIFY PATIENT POPULATIONS FOR CLINICAL TRIALS- A CASE STUDY IN METASTATIC BREAST CANCER

    Oct 1, 2018, 00:00

  • PDB12 - CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS- SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONS

    Oct 1, 2018, 00:00

  • PCV38 - BUDGET IMPACT OF ALIROCUMAB IN THE MANAGEMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS IN ARGENTINA

    Oct 1, 2018, 00:00

  • PDB110 - TREATMENT PERSISTENCE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH GLP-1 RECEPTOR AGONISTS IN CLINICAL PRACTICE IN SWEDEN- NATIONWIDE RETROSPECTIVE COHORT STUDY

    Oct 1, 2018, 00:00

  • PMD137 - CARDIAC IMPLANT REGISTRIES 2006-2016- SYSTEMATIC REVIEW OF GLOBAL PRACTICES

    Oct 1, 2018, 00:00

  • PMU123 - THE RELATIONSHIP BETWEEN INDIVIDUAL-LEVEL DEPRIVATION WITH HEALTH-RELATED QUALITY OF LIFE IN THE GENERAL POPULATION

    Oct 1, 2018, 00:00

  • RM2 - MIXTURE METHODS INCORPORATING GENERAL POPULATION MORTALITY IN THE LIKELIHOOD FUNCTION OF PARAMETRIC DISTRIBUTIONS

    Oct 1, 2018, 00:00

  • PHP341 - ARE THERE ENOUGH REGULATIONS TO COMBAT THE POOR QUALITY POVIDONE-IODINE IN EGYPT

    Oct 1, 2018, 00:00

  • PHP220 - OLD DRUGS TURNED NEW FOR ULTRA ORPHAN DISEASE- A CHALLENGE FOR PAYERS OR FOR THE INDUSTRY?

    Oct 1, 2018, 00:00

  • PCV8 - IMPACT OF EXERCISE-BASED REHABILITATION IN PATIENTS WITH HEART FAILURE (EXTRAMATCH II) ON EXERCISE CAPACITY AND HEALTH-RELATED QUALITY OF LIFE- A META-ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM RANDOMISED TRIALS

    Oct 1, 2018, 00:00

  • PMD134 - MEDICAL DEVICE APPRAISAL IN THE UK- WHAT ARE THE COMMON PITFALLS OF MANUFACTURER LITERATURE REVIEWS?

    Oct 1, 2018, 00:00

  • PCN309 - DIVERSITY IN SAFETY DATA ANALYSES IN GERMAN AMNOG BENEFIT ASSESSMENTS FOR MULTIPLE MYELOMA

    Oct 1, 2018, 00:00

  • PMS38 - COST EFFECTIVENESS ANALYSIS OF SECUKINUMAB VERSUS USTEKINUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PND158 - CHANGES IN SLEEP PATTERNS AFTER VAGUS NERVE STIMULATION, DEEP BRAIN STIMULATION OR EPILEPSY SURGERY- SYSTEMATIC REVIEW OF THE LITERATURE

    Oct 1, 2018, 00:00

  • PHP136 - CHANGES IN THE NUMBER OF PHYSIOTHERAPIST WORKFORCE IN EUROPEAN COUNTRIES BETWEEN 2000-2015

    Oct 1, 2018, 00:00

  • PMS101 - EVAULATION OF OUTCOMES AND PHYSIOTERAPY REHABILITATION AFTER DIRECT ANTERIOR APPROACH OF TOTAL HIP ARTHROPLASTY COMPARED TO CONVENTIONAL ANTEROLATERAL APPROACH

    Oct 1, 2018, 00:00

  • PHP238 - CARER DISUTILITY- IS IT ACCURATELY CAPTURED IN NICE APPRAISALS?

    Oct 1, 2018, 00:00

  • PIN76 - IMPACT OF TRANSFERRING ARTS DISPENSING FROM HOSPITAL TO COMMUNITY PHARMACIES- A PILOT STUDY IN PORTUGAL

    Oct 1, 2018, 00:00

  • PHP15 - NEW TREATMENT METHODS AND REIMBURSEMENT- EXPERIENCES IN GERMANY 2018

    Oct 1, 2018, 00:00

  • PIH46 - ANALYSING THE ATTITUDE OF OLD AGE HOME RESIDENTS ON POLYPHARMACY AND DEPRESCRIBING OF MEDICATIONS IN MANGALORE, KARNATAKA.

    Oct 1, 2018, 00:00

  • PCN304 - APPROPRIATE COMPARATOR IN GERMAN AMNOG BENEFIT ASSESSMENTS IN MELANOMA – A DYNAMIC SITUATION

    Oct 1, 2018, 00:00

  • PSY152 - IMPACT OF FATIGUE ON RESOURCE UTILIZATION AND HEALTHCARE COSTS IN AUTOIMMUNE (AI) DISEASE

    Oct 1, 2018, 00:00

  • PHP11 - HOW TO RESOLVE ISSUES EXPERIENCED BY PATIENTS IN EARLY PHASE DEVELOPMENT OF PHARMACEUTICAL PRODUCTS

    Oct 1, 2018, 00:00

  • PCN118 - THE BURDEN OF CANCER IN SPAIN

    Oct 1, 2018, 00:00

  • PDB63 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC HEART FAILURE BASED ON SUBGROUP OF EMPA-REG OUTCOME IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PND132 - ECONOMIC BURDEN OF MIGRAINE IN BRAZIL- RESULTS FROM MY MIGRAINE VOICE SURVEY

    Oct 1, 2018, 00:00

  • PCV131 - IMPACT OF TIMELY INITIATION OF ANTIHYPERTENSIVE MEDICATIONS FOR PATIENTS WITH HYPERTENSION OR ELEVATED BLOOD PRESSURE

    Oct 1, 2018, 00:00

  • PSS48 - PARENTS’ BELIEFS AND KNOWLEDGE ABOUT THE MANAGEMENT OF OTITIS MEDIA IN UNAIZAH, SAUDIARABIA- A QUALITATIVE STUDY

    Oct 1, 2018, 00:00

  • PCN205 - OUTCOMES OF DECISION AIDS USED IN ONCOLOGY- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PMU35 - COST COMPARISON OF COMPLEMENTARY AND ALTERNATIVE MEDICINE SPECIALIZED UNIT IN SUS

    Oct 1, 2018, 00:00

  • PIN56 - COST-EFFECTIVENESS OF VARICELLA AND HERPES ZOSTER VACCINATION IN THE SWEDISH POPULATION

    Oct 1, 2018, 00:00

  • PND125 - THE ASSOCIATION BETWEEN UTILITIES AND DISEASE SEVERITY FOR PARKINSON’S DISEASE- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCV3 - IMPROVING ASPIRIN TOXICITY THROUGH PRECISION MEDICINE

    Oct 1, 2018, 00:00

  • PHP278 - GUIDELINES IN GERMAN EARLY BENEFIT ASSESSMENT – WHICH GUIDELINES ARE CONSIDERED BY FEDERAL JOINT COMMITTEE FOR DETERMINING THE APPROPRIATE COMPARATOR?

    Oct 1, 2018, 00:00

  • PHP235 - INDIRECT TREATMENT COMPARISONS (ITC) FOR HTA IN EUROPE – UNDERSTANDING REQUIREMENTS FOR INDUSTRY SUBMISSIONS

    Oct 1, 2018, 00:00

  • PUK1 - DR RAJA AHSAN AFTAB

    Oct 1, 2018, 00:00

  • PSY215 - MEASURING QUALITY OF LIFE FOR ECONOMIC EVALUATION IN DUCHENNE MUSCULAR DYSTROPHY (DMD) FROM CHILDHOOD TO ADULTHOOD- PROTOCOL FOR A NEW PREFERENCE-BASED MEASURE

    Oct 1, 2018, 00:00

  • PMD140 - OUT-OF-POCKET PAYMENTS FOR MEDICAL DEVICES AND EQUITY IN HEALTHCARE FOR PATIENTS WITH PRIMARY LYMPHEDEMA IN FRANCE

    Oct 1, 2018, 00:00

  • PCN274 - TIME TO PRICE CHANGE FOLLOWING HTA DECISIONS

    Oct 1, 2018, 00:00

  • PCP15 - WHY EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENT MAY FAIL?

    Oct 1, 2018, 00:00

  • PCP18 - EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENT- A MARKER OF HTA FAILURE?

    Oct 1, 2018, 00:00

  • PCN266 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH BLADDER CANCER IN SPAIN

    Oct 1, 2018, 00:00

  • PSS67 - UNDERSTANDING THE PATIENT EXPERIENCE OF PRESBYOPIA AND IDENTIFICATION OF PATIENT-REPORTED OUTCOME ASSESSMENTS- A LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMD159 - ASSESSMENT OF THE MARKET ACCESS POTENTIAL OF A NOVEL MEDICAL DEVICE AND APP COMBINATION FOR AN ORPHAN DISEASE

    Oct 1, 2018, 00:00

  • PMD114 - ASSESSING AND MODELING ORGANIZATIONAL IMPACT OF TILMANOCEPT IN PERFORMING SENTINEL LYMPH NODE BIOPSY IN FRANCE

    Oct 1, 2018, 00:00

  • PDB62 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN JAPAN BASED ON RESULTS FROM THE SUBGROUP ANALYSIS OF ASIAN PATIENTS IN THE EMPA-REG OUTCOME TRIAL

    Oct 1, 2018, 00:00

  • PCN36 - THE EFFECT OF INTRODUCING NIVOLUMAB IN THE ADJUVANT TREATMENT SETTING OF MALIGNANT MELANOMA

    Oct 1, 2018, 00:00

  • PIH6 - DEVELOPMENT AND VALIDATION OF A SCREENING QUESTIONNAIRE TO DETECT HEAVY MENSTRUAL BLEEDING IN GYNAECOLOGY- THE SAMANTA QUESTIONNAIRE

    Oct 1, 2018, 00:00

  • PMS3 - INFLIXIMAB FOR DISEASE-MODIFYING ANTI-RHEUMATIC DRUG-NAIVE RHEUMATOID ARTHRITIS PATIENTS- SYSTEMATIC REVIEW AND DESCRIPTIVE ANALYSIS OF PUBLICATIONS OF RANDOMIZED CONTROLLED TRIALS

    Oct 1, 2018, 00:00

  • PDB29 - TYPE 2 DIABETES- DISCONTINUATION OF ANTIDIABETIC DRUG DISPENSING 8 YEARS AFTER STARTING TREATMENT- A NATIONWIDE COHORT STUDY USING THE FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS)

    Oct 1, 2018, 00:00

  • PMU63 - EFFICIENCY ASSESSMENT IN PRIMARY HEALTHCARE CENTERS OF A HEALTH DISTRICT

    Oct 1, 2018, 00:00

  • PHP296 - MANAGED ACCESS AGREEMENTS (MAAS) AND CONTINUING DATA COLLECTION AFTER PROVISIONAL POSITIVE RECOMMENDATION FROM THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Oct 1, 2018, 00:00

  • PCV48 - TOTAL ANNUAL HEALTHCARE COSTS OF HEART FAILURE BETWEEN 2005 AND 2014- A RETROSPECTIVE, POPULATION-BASED STUDY IN SWEDEN

    Oct 1, 2018, 00:00

  • PDB132 - TYPE 2 DIABETES TREATMENT PATHS AND PATIENT OUTCOMES IN RESPONSE TO REIMBURSEMENT POLICY CHANGE IN FINLAND

    Oct 1, 2018, 00:00

  • PMU91 - USE OF EQ-5D IN CENTRAL AND EASTERN EUROPE 2000-2015- NEUROLOGICAL DISORDERS

    Oct 1, 2018, 00:00

  • PHP350 - PERFORMANCE AND OUTCOMES BASED CONTRACTS IN THE EU AND USA- COMPARISON OF TRENDS AND RECENT DEVELOPMENTS

    Oct 1, 2018, 00:00

  • PCV133 - ADHERENCE SUPPORT IN COMMUNITY PHARMACIES - THE PERCEPTION OF GERMAN PHARMACISTS

    Oct 1, 2018, 00:00

  • PHP163 - THE FRENCH HEALTH ECONOMIC RESEARCH PROGRAM(PRME)- AN OVERVIEW SINCE ITS CREATION IN 2013

    Oct 1, 2018, 00:00

  • PRM174 - OPERATING SYSTEM UPGADES DO NOT ADVERSELY AFFECT ECOA COMPLETION BEHAVIOR WHEN USING A BRING YOUR OWN DEVICE (BYOD) APP.

    Oct 1, 2018, 00:00
  • «
  • 61
  • 62
  • 63
  • 64
  • 65 (current)
  • 66
  • 67
  • 68
  • 69
  • 70
  • »